2Chouaib S.Move insights into the complex physiology of TNF-α〔J〕[].Immunology Today.1991
3Stasi R,Zinnani PL,Galieni P,et al.Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed agressive non-Hodgkin′s lymphoma〔J〕[].European Journal of Haematology.1995
4Klein B,Zhang XG,Jourdan M,et al.Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by inteleukin-6〔J〕[].Blood.1989
5Durie BGM.Staging and kinetics of multiple myeloma〔J〕[].Seminars in Oncology.1986
2Coleman RE.The clinical use of bone resorption markers in patients with malignant bone disease[J].Cancer,2002,94(10):2521.
3Costa L,Demers LM,Gouveia-Oliveira A,et al.Prospec-tive evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predictingbonemetastases status[J].J Clin Oncol,2002,20(3):850.
4Ali SM,Demers LM,Leitzel K,et al.Baseline serumNTx levels are prog-nostic in metastatic breast cancer patients with bone-only metastasis[J].Ann Oncol,2004,15(3):455.
5Garnero P,FerrerasM,KarsdalMA,et a.l The type I colla-gen frag-ments ICTP and CTx reveal distinct enzymatic pathways of bone collagen degradation[J].J BoneMinerRes,2003,18(5):859.
6KoizumiM,Yonese J,Fukui I,et a.l The serum level of the amin-termicalpropeptide of type I procollagen is a sensitive-marker fo prostate cancermetastasis to bone[J].BJU Int,2001,87(4):348.
8Mohammadzadeh M,Alikhah H,Zareh AG.Comparison of bone scan with carbohydrate antigen15-3for evaluation of bone metastasis of brest cancer.Pak J Biol Sci,2010,13(4):175.
9Grana X,Reddy EP.Cycle control in mammalian cells:role of cyc-lins,cyclin dependentkinases(CDKS),growth sup-pressor genes and cyc-lin-dependentkinase inhibitors(CKIS).Oncogene,1995,11(2):211.
10Capeller B,Caffier H,Sutterlin MW,et al.Evaluation of tartrate-resistant acid phosphatase(TRAP)5b as serum marker of bone metastases in human breast cancer[J].Anticancer Res,2003,23(2A):1011.
